About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.
minkabu the infonoid
(C) 2024 MINKABU THE INFONOID, Inc.
kabutan

Modalis Therapeutics Corporation(4883) Summary

4883
TSE Growth
Modalis Therapeutics Corporation
76
JPY
+4
(+5.56%)
Apr 10, 3:30 pm JST
0.51
USD
Apr 10, 2:30 am EDT
Result
PTS
outside of trading hours
77.8
Apr 10, 3:30 pm JST
Summary Chart Historical News Financial Result
PER
PBR
1.59
Yield
ー%
Margin Trading Ratio
5,129.87
Stock Price
Apr 10, 2025
Opening Apr 10, 9:00 am
77 JPY 0.52 USD
Previous Close Apr 9
72 JPY 0.49 USD
High Apr 10, 9:02 am
78 JPY 0.53 USD
Low Apr 10, 9:23 am
74 JPY 0.50 USD
Volume
2,342,500
Trading Value
0.18B JPY 1.22M USD
VWAP
76.45 JPY 0.52 USD
Minimum Trading Value
7,600 JPY 51 USD
Market Cap
5.59B JPY 0.04B USD
Number of Trades
718
Liquidity & Number of Trades
As of Apr 10, 2025
Liquidity
High
1-Year Average
1,869
1-Year High Jul 30, 2024
20,678
Margin Trading
Date Short Interest Long Margin Positions Ratio
Apr 4, 2025 0 12,671,700
Mar 28, 2025 0 13,782,800
Mar 21, 2025 0 13,679,200
Mar 14, 2025 0 13,915,400
Mar 7, 2025 0 14,271,600
Company Profile
Modalis Therapeutics Corporation conducts research and development of gene therapy drugs using its proprietary genome editing platform. The company has a base in the United States.
Sector
Pharmaceuticals
Modalis Therapeutics Corporation utilizes its proprietary genome editing platform, centered on CRISPR-GNDM technology, to research and develop gene therapy drugs. This technology functions as a "gene switch" that can control gene expression without cutting DNA, offering higher safety compared to conventional genome editing methods. The company aims to address genetic diseases, which are often in the rare disease category and inefficient to develop using traditional drug discovery approaches, by leveraging its technological prowess. Modalis employs a hybrid business model, combining partnerships with pharmaceutical companies ("collaboration model") and in-house development ("proprietary model"). The collaboration model aims for early revenue generation, while the proprietary model targets larger future revenues. The company has several ongoing development pipelines and aims to secure licensing agreements at specific stages of development.